Alzheimer's Disease: stem cells can repair the hippocampus

Please Help Support Alzheimer's Research Today!
You r Alzhei me r's do na tion will help billi ons liv e with out it. Donate on line now
Endogenous Stem Cells Activators, Inc. is a new Nevada Corporation whose main asset is KRONOS IV. KRONOS IV is a drug that activates the dormant stem cells in the brain of AD patients, and coaxes them through a process of neurogenesis, as evidenced by the presence of growth factors (GFs) into becoming active neurons.

These cells can repair or rebuild the hippocampus, an area of the brain where memory is located, that is severely damaged by the AD. KRONOS IV is based upon a drug(s) presently available on the market that had been approved by the FDA for a different claim. As such KRONOS IV would be available to the AD patients upon prescription by a physician, based upon the off-label regulations that allow physicians to prescribe drugs for medical conditions, other than the one approved by the FDA. We have reasons to believe that KRONOS IV will be available before the end of the year, at a tentative price of $1200 a month, or a total of $7200 for six months treatment.

KRONOS IV in its initial phases had been used by 10-12 physicians in the US and France who reported impressive results in the areas of memory, attention, orientation, also in controlling incontinences, and most importantly in improving the Quality of Life (QoL) of the AD's family members living under a continuous high stress. First KRONOS results had been reported at the Second International Symposium on Stress, Monte Carlo, Monaco November 21st, 1979 honored by the participation of four Nobel Prize winners, Dr. Jonas Salk and top scientists from 10+ countries.

Subsequently a positive commentary about KRONOS presentation at the Symposium had been published in JAMA (Journal of American Medical Association), April 25th, 1980. KRONOS IV is our response to the call for help, now, from the families of the 5.3 million patients with AD, who know well that in the next 4-5 years, few if any survivors would be around, plus another 5.3 MM new AD patients that would be entering the Alzheimer's inferno, soon. ... http://www.medicalnewstoday.com

Lipid Nutrition enters vitamin E market

Lipid Nutrition has launched a branded version of rising vitamin E form, tocotrienol, which a growing body of science is backing as one of the most powerful in antioxidant payload. ...http://www.nutraingredients.com